8-K: Windtree Therapeutics Secures $253K in Convertible Note and Warrant Financing Amidst Stringent Terms

Windtree Therapeutics, Inc. has raised $253,333 in gross proceeds through the issuance of senior unsecured convertible promissory notes and warrants to fund operational expenses, under terms indicating significant financial pressure.

Summary

• Windtree Therapeutics, Inc. completed a financing round, issuing senior unsecured convertible promissory notes and warrants.
• The company received gross proceeds of $253,333 from these sales.
• The financing occurred in two tranches: June 27, 2025, and July 2, 2025.
• The June 27, 2025 tranche involved two notes with principal amounts of $58,140 and $96,899, for purchase prices of $50,000 and $83,333, respectively.
• The July 2, 2025 tranche involved two notes, each with a principal amount of $40,698, for a purchase price of $35,000 each.
• The notes accrue interest at 14% per annum, compounding quarterly, and mature 12 months from their issue date.
• The conversion price for the notes is $0.587 per share of common stock.
• Warrants were issued for an amount equal to 25% of the purchase price paid by each investor, with an exercise price of $1.10 per share.
• Proceeds will be used for general operational expenses, including a loan to Titan Environmental Services, Inc.
• The notes are subordinated to an existing convertible promissory note with DFU, LLC dated June 6, 2025.

Sentiment

Score: 3

Explanation: The financing provides much-needed capital for operational expenses, which is a positive for continued business. However, the terms are highly dilutive and expensive for the company, with a high interest rate and significant investor protections, suggesting a distressed financing scenario. The subordination to existing debt further weakens the company's position. This indicates a challenging financial situation.

Positives

• Secured $253,333 in gross proceeds, providing necessary capital for operational expenses and a loan to a subsidiary.
• The company retains the option to prepay the notes, offering some flexibility in debt management.
• The company is required to file a registration statement for the resale of shares, which could facilitate liquidity for investors.

Negatives

• The purchase price for the convertible notes is less than the principal amount, indicating an immediate discount for investors and a higher effective cost of capital for the company.
• The 14% annual interest rate on the notes, escalating to 24% upon an Event of Default, represents a very high cost of debt.
• The notes are subordinated to an existing convertible promissory note with DFU, LLC, placing these new noteholders in a secondary position for repayment.
• The issuance of convertible notes and warrants will lead to significant dilution for existing shareholders upon conversion/exercise.
• The company is restricted from entering into certain 'Variable Rate Transactions' unless a 50% floor price relative to market price is maintained, potentially limiting future financing flexibility.
• The company is subject to liquidated damages of $2,000 per day if it fails to deliver common stock upon conversion by the deadline.
• Liquidated damages of $50,000 are assessed if the company fails to include conversion and warrant shares in a registration statement.
• The company is obligated to repay the notes from proceeds of most future securities issuances, with limited exceptions, potentially forcing early repayment.

Risks

• Failure to pay principal or interest, breach of covenants, or breach of representations and warranties can trigger an Event of Default, leading to immediate acceleration of the note at 110% (or higher) of principal plus accrued interest.
• Judgments over $50,000 remaining unvacated, unbonded, or unstayed for 20 days constitute an Event of Default.
• Cessation of operations or admission of inability to pay debts (excluding going concern disclosure) is an Event of Default.
• Failure to maintain material intellectual property or assets, or disposition of material assets, constitutes an Event of Default.
• Restatement of financial statements that materially adversely affects holder rights is an Event of Default.
• Delisting of common stock from NASDAQ or cessation of trading for five consecutive days are Events of Default.
• Failure to comply with Exchange Act reporting requirements (e.g., delinquent filings, ceasing to be subject to reporting, not having public information for Rule 15c2-11(b)) is an Event of Default.
• Loss of DTC DWAC/FAST electronic transfer ability or DTC eligibility, or issues with the transfer agent (e.g., balance owed) are Events of Default.
• The company acknowledges the potentially dilutive effect of issuing conversion shares and warrant shares on existing common stock.
• Restrictions on variable rate transactions and the obligation to repay notes from future financing proceeds could limit the company's ability to raise capital efficiently in the future.
• Inability to obtain a Rule 144 legal opinion or deposit shares into a brokerage account is an Event of Default.
• Effectuating a reverse split of common stock is an Event of Default.

Future Outlook

The company intends to use the proceeds from this financing to fund operational expenses, including a loan to Titan Environmental Services, Inc. The company also commits to filing a registration statement for the resale of the newly issued shares and warrants within 20 trading days, indicating a plan to facilitate future liquidity for investors.

Management Comments

• Jed Latkin, President and Chief Executive Officer of Windtree Therapeutics, Inc., signed the filing on behalf of the company.

Industry Context

This financing represents a common strategy for development-stage biotechnology or pharmaceutical companies like Windtree Therapeutics, Inc. to secure capital for ongoing operations and potential strategic initiatives. The use of convertible notes and warrants is a flexible financing tool, often employed by companies that may not have significant revenue streams but require capital for R&D, clinical trials, or general corporate purposes. The high interest rate and dilutive nature of the securities suggest a company in need of capital, typical for firms in the pre-commercialization phase of the biotech industry.

Comparison to Industry Standards

• The 14% annual interest rate on convertible notes is relatively high, suggesting a higher perceived risk by investors compared to more established biotech companies or those with late-stage assets. For example, a more mature biotech firm might secure debt at single-digit interest rates.
• The conversion price of $0.587 per share and warrant exercise price of $1.10 per share indicate that investors are receiving equity at a discount to the current market price (implied by the principal amount being higher than the purchase price for the notes) and warrants with a premium, which is a common structure for such financings in the small-cap biotech space.
• The inclusion of significant liquidated damages clauses for failure to deliver shares or register securities is a strong protective measure for investors, often seen in financings with companies that have a history of capital structure complexities or liquidity challenges.
• The subordination to the DFU, LLC note is a critical detail, indicating a layered capital structure and potentially higher risk for these new noteholders compared to senior secured debt typically seen in larger, more stable companies.

Stakeholder Impact

• Shareholders: Significant potential for dilution due to the conversion of notes at $0.587 per share and exercise of warrants at $1.10 per share. Existing shareholders' ownership percentage will decrease.
• Creditors: The new convertible notes are senior unsecured but subordinated to an existing DFU, LLC note, impacting their recovery priority.
• Company Operations: The capital infusion provides funds for operational expenses and a loan to a subsidiary, which could support ongoing business activities.

Next Steps

• Company to file a registration statement (Form S-1 or S-3) within 20 Trading Days from the Execution Date to register the offering and resale of the Conversion Shares and Warrant Shares.
• Company to maintain listing of Common Stock on NASDAQ.
• Company to comply with Exchange Act reporting requirements.
• Company to maintain engagement with a PCAOB registered accounting firm.
• Company to provide prior notification to holders of corporate events, including shareholder meetings and distributions.

Key Dates

Recommendation

Keywords

Convertible Notes, Warrants, Debt Financing, Equity Financing, Capital Raise, Dilution, SEC Filing, 8-K, Corporate Governance, Risk Factors, NASDAQ, WINT, Windtree Therapeutics